FOXO4-DRI
Very early researchThe research is at the earliest stage – mostly cells in a lab dish. It is far too early to say much.
Also called FOXO4 D-Retro-Inverso / Proxofim
Designed to clear out old, damaged cells. Studied only in cells and mice so far.
Can a doctor prescribe this?
No. Pharmacies are not on record as being allowed to make this into a medicine.
The FDA has not approved this as a medicine.
Not approved and not on the compounding list.
Official status: Not on the 503A bulks list. Checked 2026-08-04.
Lab suppliers we list: 5
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
No dosing information has been published in the research indexed here.
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.
Animal study, rats or mice
Frontiers in bioengineering and biotechnology · 2025
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells.
Animal study, rats or mice
Experimental gerontology · 2024
- Cellular Senescence Contributes to the Progression of Hyperoxic Bronchopulmonary Dysplasia.
Animal study, rats or mice
American journal of respiratory cell and molecular biology · 2024
- FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice.
Animal study, rats or mice
Naunyn-Schmiedeberg's archives of pharmacology · 2023
- FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.
Lab dish study
Journal of cellular and molecular medicine · 2022
- Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis.
Lab dish study
JCI insight · 2021
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From <i>in vitro</i> Expanded Human Chondrocytes.
Lab dish study
Frontiers in bioengineering and biotechnology · 2021
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
Lab dish study
Aging · 2020
- Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence.
Molecular carcinogenesis · 2026
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.
Communications biology · 2025
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.
Nature communications · 2025
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.
Review of earlier work
Naunyn-Schmiedeberg's archives of pharmacology · 2026
- FOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence: Cysteine-Based Signaling, p53 Interaction, and Therapeutic Targeting.
Review of earlier work
Antioxidants (Basel, Switzerland) · 2026